SCHEMBL2213005

SCHEMBL2213005

N#Cc1ccc(-c2nnc(Nc3ccc(Oc4ccnc5cc(C#N)ccc45)cc3)c3ccccc23)cc1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
IKBKB O14920 1/20 0.46
FGFR2 P21802 2/20 0.46
MAPT P10636 6/20 0.45
LMNA P02545 1/20 0.45
POLB P06746 1/20 0.45
ENPP3 O14638 3/20 0.44
GAA P10253 2/20 0.44
TP53 P04637 2/20 0.44
CA2 P00918 1/20 0.44
CA9 Q16790 1/20 0.44
KDR P35968 2/20 0.43
ALK Q9UM73 1/20 0.43
AURKA O14965 2/20 0.43
AURKB Q96GD4 2/20 0.43
TPX2 Q9ULW0 2/20 0.43
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
ACP1 P24666 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2209486 0.96 FGFR2 (0.48) IKBKBFGFR2MAPTLMNAPOLB
SCHEMBL2208492 0.95 KDR (0.46) IKBKBFGFR2MAPTLMNAPOLB
SCHEMBL2208494 0.95 MAPT (0.54) FGFR2MAPTLMNAPOLBENPP3
SCHEMBL2211970 0.95 AURKA (0.48) FGFR2MAPTLMNAPOLBENPP3
SCHEMBL2211365 0.92 KDR (0.44) IKBKBFGFR2MAPTLMNAPOLB
SCHEMBL2207468 0.90 FGFR2 (0.41) IKBKBFGFR2MAPTLMNAPOLB
SCHEMBL2211314 0.90 MAPT (0.43) IKBKBFGFR2MAPTLMNAPOLB
SCHEMBL2211183 0.89 FGFR2 (0.48) FGFR2MAPTLMNAPOLBENPP3
SCHEMBL2207110 0.87 FGFR2 (0.48) FGFR2KDRAURKAAURKBTPX2
SCHEMBL3732592 0.87 FGFR2 (0.42) IKBKBFGFR2MAPTLMNAENPP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7981891-B2 Aurora kinase modulators and method of use AMGEN INC. (US) 2011-07-19 US claimed
US-20100280008-A1 AURORA KINASE MODULATORS AND METHOD OF USE AMGEN INC. (US) 2010-11-04 US claimed
EP-2137177-B1 AURORA KINASE MODULATORS AND METHOD OF USE AMGEN INC (US) 2014-05-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100280008-A1 AURORA KINASE MODULATORS AND METHOD OF USE AURKC, AURKA, CDK1 IKBKB 524/4885FGFR2 334/4885MAPT 1693/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.